Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson’s disease

References

• Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron39(6), 889–909 (2003).
   PubMed Web of Science ®Google Scholar
• Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson’s disease. Arch. Neurol.62(3), 353–357 (2005).
   PubMedGoogle Scholar
• Dandhi S, Wood NW. Molecular pathogenesis of Parkinson’s disease. Hum. Mol. Genet.14(18), 2749–2755 (2005).
   Google Scholar
• Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson’s disease: molecules to medicine. J. Clin. Inv.116(7), 1744–1754 (2006).
   PubMed Web of Science ®Google Scholar
• Thomas B, Beal MF. Parkinson’s disease. Human Mol. Genet.16(Spec. No.2), R183–R194 (2007).
   PubMed Web of Science ®Google Scholar
• Vila M, Przedborski S. Genetic clues to the pathogenesis of Parkinson’s disease. Nat. Med.10(Suppl.), S58–S62 (2004)
   PubMedGoogle Scholar
• Sun F, Kanthasamy A, Anantharam V, Kanthasamy AG. Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson’s disease. Pharmacol. Ther.114(3), 327–344 (2007).
   PubMedGoogle Scholar
• Bogaerts V, Theuns J, van Broeckhoven C. Genetic findings in Parkinson’s disease and translation into treatment: a leading role for mitochondria? Genes Brain Behav.7(2), 129–151 (2008).
   PubMed Web of Science ®Google Scholar
• Terzioglu M, Galter D. Parkinson’s disease: genetic versus toxin-induced rodent models. FEBS J.275(7), 1384–1391 (2008).
   PubMed Web of Science ®Google Scholar
• Ethell DW, Fei Q. Parkinson-linked genes and toxins that affect neuronal cell death through the Bcl-2 family. Antiox. Redox Signal.11(3), 1–12 (2009).
   PubMedGoogle Scholar
• Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosis in Parkinson’s disease: signals for neural degradation. Ann. Neurol.53(Suppl.), S61–S72 (2003).
   PubMed Web of Science ®Google Scholar
• Esposito E, Matteo VD, Giovanni GD. Death in the substantia nigra: a motor tragedy. Expert Rev. Neurother.7(6), 677–697 (2007).
   PubMedGoogle Scholar
• Dick FD, De Palma G, Almadi A et al. Environmental risk factors for Parkinson’s disease and parkinsonism: the Geoparkinson study. Occup. Environ. Med.64(10), 666–672 (2007).
   PubMed Web of Science ®Google Scholar
• Bonsi P, Cuomo D, Martella G et al Mitochondrial toxins in basal ganglia disorders: from animal models to therapeutic strategies. Curr. Neuropharmacol.4(1), 69–75 (2006).
   PubMedGoogle Scholar
• Naoi M, Maruyama W, Nagy GM. Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: occurrence, metabolism and function in human brain. Neuro. Toxicol.25(1–2), 193–204 (2004).
   Google Scholar
• Abou-Sleiman PM, Muqit MMK, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat. Rev. Neurosci.7(3), 207–219 (2006).
   PubMed Web of Science ®Google Scholar
• Lesage S, Brice A. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet.18(R1), R48–R59 (2009).
   PubMed Web of Science ®Google Scholar
• Waldmeier PC, Tatton WG. Interrupting apoptosis in neurodegenerative disease: potential for effective therapy? Drug Discov. Today9(5), 210–218 (2004).
   PubMedGoogle Scholar
• Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson’s disease. Trends Neurosci.30(5), 244–250 (2007).
   PubMed Web of Science ®Google Scholar
• Fischer U, Sculze-Osthoff K. New approaches and therapeutic targeting apoptosis in disease. Pharmacol. Rev.57(2), 187–215 (2005).
   PubMed Web of Science ®Google Scholar
• Green DR, Kroemer G. Pharmacological manipulation of cell death: clinical applications in sight? J. Clin. Invest.115(10), 2610–2617 (2005).
   PubMed Web of Science ®Google Scholar
• Braak H, Tredici KD, Rüb U, de Vos RAL, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging24(2), 197–211 (2003).
   PubMed Web of Science ®Google Scholar
• Braak H, Ghebremedhin E, Rüb U, Bratzke H, Tredici KD. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res.318(1), 121–134 (2004).
   PubMed Web of Science ®Google Scholar
• Török TL, Klebovich I. Monoamine Oxidase Inhibitors and Their Role in Neurotransmission (Drug Development). Medicina Publishing House (Eds). Budapest, Hungary 1–403 (2004).
   Google Scholar
• Schapira AHV, Olanow AW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA291(3), 358–364 (2004).
   PubMed Web of Science ®Google Scholar
• Jenner P. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson’s disease. Neurology63(Suppl. 2), S13–S31 (2004).
   PubMedGoogle Scholar
• Schapira AH, Bezard E, Brotchie J et al. Novel pharmacological targets for the treatment of Parkinson’s disease. Nat. Rev. Drug Discov.5(10), 845–854 (2006).
   PubMed Web of Science ®Google Scholar
• Elmer LW, Bertoni JM. The increasing role of monoamine oxidase type B inhibitors in Parkinson’s disease therapy. Expert Opin. Pharmacother.9(16), 2759–2772 (2008).
   PubMed Web of Science ®Google Scholar
• Edmondson DE, Mattevi A, Binda C, Li M, Hubalek F. Structure and mechanism of monoamine oxidase. Cur. Med. Chem.11(15), 1983–1993 (2004).
   PubMed Web of Science ®Google Scholar
• Edmondson DE, Binda C, Mattevi A. Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Arch. Biochem. Biophys.464(2), 269–276 (2007).
   PubMed Web of Science ®Google Scholar
• Shih JC. Monoamine oxidases: from tissue homogenates to transgenic mice. Neurochem. Res.32(10), 1757–1761 (2007).
   PubMedGoogle Scholar
• Kumar MJ, Anderson JK. Perspectives on MAO-B in aging and neurological disease. Mol. Neurobiol.30(1), 77–89 (2004).
   PubMed Web of Science ®Google Scholar
• Parsian A, Racette B, Zhang ZH, Rundle M, Perlmutter JS. Association of variations in monoamine oxidases A and B with Parkinson’s disease subgroups. Genomics83(3), 454–460 (2004).
   PubMed Web of Science ®Google Scholar
• Cordata DJ, Chan DKY. Genetics and Parkinson’s disease J. Clin. Neurosci.11(2), 119–123 (2004).
   PubMedGoogle Scholar
• Bialecka M, Klodowska-Duda G, Honczarenko K et al. Polymorphisms of catechol-O-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2), and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson’s disease. Parkinsonism Relat. Disord.13(4), 224–229 (2007).
   PubMed Web of Science ®Google Scholar
• Singh M, Khan AJ, Shah PP, Shukla R, Khanna VK, Parmar D. Polymorphism in environment responsive genes and association with Parkinson disease. Mol. Cell Biochem.312(1–2), 131–138 (2008).
   PubMed Web of Science ®Google Scholar
• Gao X, Scott WK, Wang G et al. Gene–gene interaction between FGF20 and MAOB in Parkinson disease. Ann. Human Genet.72(Pt 2), 157–162 (2008).
   PubMedGoogle Scholar
• Alia-Klein N, Goldstein RZ, Kriplani A et al. Brain monoamine oxidase A activity predicts trait aggression. J. Neurosci.28(19), 5099–5104 (2008).
   PubMed Web of Science ®Google Scholar
• Wu YH, Fisher DF, Swaab DF. A promotor polymorphism in the monoamine oxidase A gene is associated with the pineal MAOA activity in Alzheimer’s disease patients. Brain Res.116, 13–19 (2007).
   Google Scholar
• Yu YW, Tsai SJ, Hong CJ, Chen TJ, Chen MC, Yang CW. Association study of a monoamine oxidase: a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropharmacology39(9), 1719–1723 (2005).
   Google Scholar
• Cohen IL, Liu X, Schutz C et al. Association of autism severity with a monoamine oxidase: a functional polymorphism. Clin. Genetics64(3), 190–197 (2003).
   PubMedGoogle Scholar
• Riederer P, Lachenmayer L, Laux G. Clinical applications of MAO-inhibitors. Curr. Med. Chem.11(13), 2033–2043 (2004).
   PubMed Web of Science ®Google Scholar
• Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci.7(4), 295–309 (2006).
   PubMed Web of Science ®Google Scholar
• Youdim MBH, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness. Br. J. Pharmacol.147(Suppl. 1), S287–S296 (2006).
   PubMed Web of Science ®Google Scholar
• Binda C, Li M, Hubalek F, Reselli N, Edmondson DE, Mattevi A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structure. Proc. Natl Acad. Sci. USA100(17), 9750–9755 (2003).
   PubMed Web of Science ®Google Scholar
• Binda C, Hubalek F, Li M et al. Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. J. Med. Chem.47(7), 1360–1366 (2004).
   PubMedGoogle Scholar
• Binda C, Hubalek F, Castagnoli N, Edmondson DE, Mattevi A. Structure of the human mitochondrial monoamine oxidase B: new chemical implications for neuroprotective drug design. Neurology67(Suppl. 2), S5–S7 (2006).
   PubMed Web of Science ®Google Scholar
• Hualek F, Binda C, Khalil A, Mattevi A, Catagnoli N, Edmondson DE. Demonstration of isoleucine 199 as a structural determination for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. J. Biol. Chem.280(22), 15761–15766 (2005).
   PubMedGoogle Scholar
• De Colibus L, Li M, Binda C, Lustig A, Edmondson DE, Mattevi A. Three-dimensional structure of human monoamine oxidase (MAO A): relation to the structures of rat MAO A and human MAO B. Proc. Natl Acad. Sci. USA102(36), 12684–12689 (2005).
   PubMed Web of Science ®Google Scholar
• Son S, Ma J, Kondou Y, Yoshimura M, Yamashita E, Tsukihara T. Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors. Proc. Natl Acad. Sci. USA105(15), 5739–5744 (2008).
   PubMed Web of Science ®Google Scholar
• Magyar K, Palfi M, Tabi T, Kalasz H, Szende B, Szoko E. Pharmacological aspects of (-)-deprenyl. Curr. Med. Chem.11(15), 2017–2031 (2004).
   PubMed Web of Science ®Google Scholar
• Muralikrishnan D, Samantary S, Mohamalumar KP. D-deprenyl protects nigro–striatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity. Synapse50(1), 7–13 (2003).
   PubMed Web of Science ®Google Scholar
• Ebadi M, Brown-Borg H, Ren J et al. Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr. Drug Targets7(11), 1513–1529 (2006).
   PubMed Web of Science ®Google Scholar
• Riederer P, Lachenmayer L. Selegiline’s neuroprotective capacity revisited. J. Neural Transm.110(11), 1273–1278 (2003).
   PubMed Web of Science ®Google Scholar
• Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikoda O, Palm R; Swedish Parkinson Study Group. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology66(8), 1200–1206 (2006).
   PubMed Web of Science ®Google Scholar
• Lev N, Melamed E, Offen D. Apoptosis and Parkinson’s disease. Prog. Neuropsycopharmacol. Biol. Psychiat.27(2), 245–250 (2003).
   PubMed Web of Science ®Google Scholar
• Malagelada C, Ryu EJ, Biswas SC, Jackson-Lewis V, Green LA. RTP801 is elevated in parkinsonian brain substantia nigral neurons and mediates death in cellular models of Parkinson’s disease by a mechanism involving mammalian target of rapamycin inactivation. J. Neurosci.26(49), 9996–10005 (2006).
   PubMed Web of Science ®Google Scholar
• Mogi M, Kondo T, Mizuno Y, Nagatsu T. p53 protein, interferon-g, and NF-κB levels are elevated in the parkinsonian brain. Neurosci. Lett.414(1), 94–97 (2007).
   PubMed Web of Science ®Google Scholar
• Nagatsu T, Sawada M. Biochemistry of postmortem brains in Parkinson’s disease: historical overview and future prospects. J. Neural Transm. Suppl.72, 113–120 (2007).
   Google Scholar
• Betartbet B, Anderson LR, Gearing M et al. Fas-associated factor 1 and Parkinson’s disease. Neurobiol. Dis.31(3), 309–315 (2008).
   PubMedGoogle Scholar
• Naoi M, Maruyama W, Akao Y, Yi H. Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines. J. Neural Transm.109(5–6), 607–621 (2002).
   PubMed Web of Science ®Google Scholar
• Akao Y, Maruyama W, Shimizu S et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and its inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J. Neurochem.82(4), 913–923 (2002).
   PubMed Web of Science ®Google Scholar
• Novikova L, Garris BL, Garris DR, Lau YS. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/pribenecid model of Parkinson’s disease. Neuroscience14(1), 67–76 (2006).
   Google Scholar
• Chin MH, Oian WJ, Wang H et al. Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striatum in two mouse models of Parkinson’s disease. J. Proteome Res.7(2), 666–677 (2008).
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W, Yi H et al. Neuromelanin selectively induces apoptosis in dopaminergic SH-SY5Y cells by deglutathionylation in mitochondria: involvement of the protein and melanin component. J. Neurochem.105(6), 2489–2500 (2008).
   PubMedGoogle Scholar
• Kinnally KW, Antinsson B. A tale of two mitochondrial channels, MAC and PTP, in apoptosis. Apoptosis12(5), 857–868 (2007)
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev.87(1), 99–163 (2007).
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Shimizu S. Role of the mitochondrial membrane permeability transition in cell death. Apoptosis12(5), 835–840 (2007).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Akao Y, Youdim MB, Davis BA, Naoi M. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous neurotoxin, N-methyl(R)salsolinol. J. Neurochem.78(4), 727–735 (2001).
   PubMed Web of Science ®Google Scholar
• Soane L, Fiskum G. TAT-mediated endocytotic delivery of the loop deletion Bcl-2 protein protects neurons against cell death. J. Neurochem.95(1), 230–243 (2005).
   PubMedGoogle Scholar
• Lin CF, Chen CL, Chang WT et al. Bcl-2 rescues ceramide- and etoposide-induced mitochondrial apoptosis through blockage of caspase-2 activation. J. Biol. Chem.280(25), 23758–23765 (2005).
   PubMedGoogle Scholar
• Malok JMI, Shevtsova Z, Bähr M, Kuugler S. Long-term in vivo inhibition of CNS neurodegeneration by Bcl-XL gene transfer. Mol. Ther.11(3), 373–381 (2005).
   PubMedGoogle Scholar
• Letal A. Pharmacological manipulation of Bcl-2 family members to control cell death. J. Clin. Invest.115(10), 2648–2655 (2005).
   PubMedGoogle Scholar
• Shacka JJ, Roth KA. Regulation of neuronal cell death and neurodegeneration by members of Bcl-2 family: therapeutic implications. Curr. Drug Targets CNS Neurol. Disord.4(1), 25–39 (2005).
   PubMedGoogle Scholar
• Soane L, Fiskum G. Inhibition of mitochondrial neural cell death pathways by protein transduction of Bcl-2 family proteins. J. Bioenerg. Biomembr.37(3), 179–190 (2005).
   PubMed Web of Science ®Google Scholar
• Shacka JJ, Roth KA. Bcl-2 family and the central nervous system: from rheostat to real complex. Cell Death Differ.13(8), 1299–1304 (2006).
   PubMedGoogle Scholar
• Liu B. RNA interference technologies for understanding and treating neurodegenerative diseases. NeuroMolecular Med.6(1), 1–12 (2004).
   PubMedGoogle Scholar
• Ralph GS, Mazarakis ND. Therapeutic gene silencing in neurological disorders, using interfering RNA. J. Mol. Med.83(6), 413–419 (2005).
   PubMed Web of Science ®Google Scholar
• Manfredsson EP, Lewin AS, Mandel RJ. RNA knockdown as a potential therapeutic strategy in Parkinson’s disease. Gene Ther.13(6), 517–524 (2006).
   PubMedGoogle Scholar
• Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M. An anti-Parkinson’s disease drug, N-propargyl-1(R)-aminoindan (rasagiline) enhances expression of antiapoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci. Lett.326(2), 105–108 (2002).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Takahashi T, Youdim M, Naoi M. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neural Transm.109(4), 467–481 (2002).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdim MBH, Naoi M. Neuroprotection by propargylamines in Parkinson’s disease. Suppression of apoptosis and induction of prosurvival genes. Neurotoxicol. Teratol.24(5), 675–682 (2002).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Yi H, Takahashi T et al Neuroprotective function of R-(-)-1-(benzofuran-2-yl)-2-propargylaminopentane, [R-(-)-BFAP] against apoptosis induced by N-methyl(R)salsolinol, an endogenous dopaminergic neurotoxin, in human dopaminergic neuroblastoma SH-SY5Y cells. Life Sci.75(1), 107–117 (2004).
   PubMedGoogle Scholar
• Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson’ disease. Exp. Neurol.187(2), 455–459 (2004).
   PubMed Web of Science ®Google Scholar
• Yi H, Maruyama W, Akao Y et al.N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J. Neural Transm.113(1), 21–32 (2006).
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W, Akao Y, Yi H, Yamaoka T. Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading cell death or neuroprotection. J. Neural Transm. Suppl.71, 67–77 (2006).
   Google Scholar
• Naoi M, Maruyama W, Yi H, Akao Y, Yamaoka Y, Shamoto-Nagai M. Neuroprotection by propargylamines in Parkinson’s disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers. J. Neural Transm. Suppl.72, 121–131 (2007).
   Google Scholar
• Mandel SA, Sagi Y, Amit T. Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway. Neurosci. Res.32(10), 1694–1699 (2007).
   Google Scholar
• Bar-Am O, Amit T, Youdim MB. Aminoindan and hydroxyaminoindan metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J. Neurochem.104(2), 500–508 (2007).
   PubMedGoogle Scholar
• Speiser Z, Mayk A, Litinetsky Let al. Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat. J. Neural Transm.114(5), 595–605 (2007).
   PubMed Web of Science ®Google Scholar
• Zhu W, Xie W, Pan Tet al. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigro–striatal dopamine degeneration. J. Neurochem.105(5), 1970–1978 (2008).
   PubMed Web of Science ®Google Scholar
• Binda C, Hubalek F, Li Met al. Binding of rasagiline-related inhibitors to human monoamine oxidases; a kinetic and crystallographic analysis. J. Med. Chem.48(26), 8148–8154 (2005).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Nitta A, Shamoto-Nagai M, et al.N-Propargyl-1-(R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF), in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor. Neurochem. Int.44(6), 293–400 (2004).
   PubMedGoogle Scholar
• Weireb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MBH. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J.18(12), 1471–1473 (2004).
   PubMedGoogle Scholar
• Bar-Am O, Weinreb O, Amit T, Youdim MB. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J.19(13), 1899–1901 (2005).
   PubMed Web of Science ®Google Scholar
• Hirai C, Takahara K, Shimizu Set al. Effects of R-(-)-BPAP on the expression of neurotrophins and their receptors in mesencephalic slices. Biol. Pharm. Bull.28(8), 1524–1526 (2006).
   Google Scholar
• Bespalov MB, Saarma M. GDNF family receptor complexes are emerging drug targets. Trends Pharmacol. Sci.28(2), 69–74 (2007).
   Google Scholar
• Zheng JS, Tang LL, Zheng SS, Zhan RY et al. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson’s disease. Brain Res. Mol. Brain Res.134(1), 155–161 (2005).
   PubMedGoogle Scholar
• Sun M, Kong L, Wang X, Lu X, Gao Q, Geller AI. Comparison of the capacity of GDNF, BDNF, or both, to protect nigrostrial neurons in a rat model of Parkinson’s disease. Brain Res.1052(2), 119–129 (2005).
   PubMed Web of Science ®Google Scholar
• Do Thi NA, Saillour P, Ferrero L, Paunio T, Mallet J. Does neuronal expression of GDNF effectively protect dopaminergic neurons in a rat model of Parkinson’s disease? Gene Ther.14(5), 441–450 (2007).
   PubMedGoogle Scholar
• Gill SS, Patel NK, Hotton GR et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson’s disease. Nat. Med.9(5), 589–595 (2003).
   PubMed Web of Science ®Google Scholar
• Lang AE, Gill S, Pael NK et al. Randomized controlled trial of intraputamenal glial cell-line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol.59(3), 459–466 (2006).
   PubMed Web of Science ®Google Scholar
• Slevin JT, Gash DM, Smith CD et al. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J. Neurosurg.106(4), 614–620 (2007).
   PubMed Web of Science ®Google Scholar
• Dietz GP, Valbuena PC, Dietz B et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson’s disease. Mol. Ther.15(1), 62–68 (2007).
   PubMedGoogle Scholar
• Grondin R, Zhang Z, Ai Yet al. Intraputamenal infusion of exogenous neurturin protein restores motor and dopaminergic function in the globus pallidus of MPTP-lesioned rhesus monkeys. Cell Transplant.17(4), 373–381 (2008).
   PubMed Web of Science ®Google Scholar
• Marks WJ, Ostrem JL, Verhagen L et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-trial, Phase 1 trial. Lancet Neurol.7(5), 400–408 (2008).
   PubMed Web of Science ®Google Scholar
• Dietz GP, Valbuena PC, Dietz B et al. Application of a blood–brain-barrier-penetrating form of GDNF in a mouse model for Parkinson’s disease. Brain Res.1082(1), 61–66 (2006).
   PubMedGoogle Scholar
• Kunikowska G, Gallagher I, Glover V, Clow A, Jenner P. Effects of short- and long-term (-)-deprenyl administration on mRNA for copper, zinc- and manganese-superoxide dismutase and glutathione peroxidase in rat brain. Brain Res.953(1–2), 1–11 (2002).
   PubMedGoogle Scholar
• Andoh T, Chock PB, Murphy DL, Chiueh CC. Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (-)-deprenyl. Mol. Pharmacol.68(5), 1408–1414 (2005).
   PubMed Web of Science ®Google Scholar
• Nakaso K, Nakamura C, Sato H, Imamura K, Takeshima T, Nakashima K. Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. Biochem. Biophys. Res. Commun.339(3), 915–922 (2006).
   PubMed Web of Science ®Google Scholar
• Takahata K, Shimizu S, Katsuki H, Yoneda F, Akaike A. Effects of selegiline on antioxidant systems in the nigrostriatum in rat. J. Neural Transm.113(2), 151–158 (2006).
   PubMedGoogle Scholar
• Sariola H, Saarma M. Novel functions and signal pathways for GDNF. J. Cell Sci.116(19), 3855–3862 (2003).
   PubMed Web of Science ®Google Scholar
• Almeida RD, Manadas BJ, Melo CV et al. Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death Differ.12(10), 1329–1343 (2005).
   PubMed Web of Science ®Google Scholar
• Reichardt LF. Neurotrophin-regulated signaling pathways. Philos. Trans. R. Soc. Lond. B361(1473), 1545–1564 (2006).
   PubMed Web of Science ®Google Scholar
• Yogev-Falach M, Amit T, Bar-Am O, Youdim MBH. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing. FASEB J.17(15), 2325–2327 (2003).
   PubMed Web of Science ®Google Scholar
• Bar-Am O, Yogev-Falach M, Amit T, Sagi Y, Youdim MBH. Regulation of protein kinase C by the anti-parkinson drug, MAO-B inhibitor rasagiline and its derivatives, in vivo. J. Neurochem.85(5), 1119–1125 (2004).
   Google Scholar
• Karin M, Lin A. NF-κB at the crossroads of life and death. Nat. Immunol.3(3), 221–227 (2002).
   PubMed Web of Science ®Google Scholar
• Camandola S, Mattson MP. NF-κB as a therapeutic target in neurodegeneration. Expert Opin. Ther. Targets11(2), 123–132 (2007).
   PubMed Web of Science ®Google Scholar
• Nifboer CG, Heijnen CJ, Groenendaal F, May MJ, van Bel F, Kavelaars A. A dual role of NF-κB pathway in neonatal-ischemic brain damage. Stroke39(9), 2578–2586 (2008).
   PubMedGoogle Scholar
• Soos J, Engelhardt JI, Siklos L, Havas L, Majtenyi K. The expression of PARP, NF-κB and parvalbumin is increased in Parkinson’s disease. Neuroreport15(11), 1715–1718 (2004).
   PubMedGoogle Scholar
• Onyango IG, Tuttle JB, Bennett JP Jr. Activation of p38 and n-acetylcysteine-sensitive c-Jun NH2-terminal kinase signaling cascade is required for induction of apoptosis in Parkinson’s disease cybrids. Mol. Cell Neurosci.28(3), 452–461 (2005).
   PubMedGoogle Scholar
• Ghosh A, Roy A, Liu X et al. Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson’s disease. Proc. Natl Acad. Sci. USA104(47), 18754–18759 (2007).
   PubMed Web of Science ®Google Scholar
• Fridmacher V, Katschmidt B, Goudeau B et al. Forebrain-specific neuronal inhibition of nuclear factor-κB activity leads to loss of neuroprotection. J. Neurosci.23(28), 9403–9408 (2003).
   PubMed Web of Science ®Google Scholar
• Jang JH, Surh YJ. Bcl-2 attenuation of oxidative cell death is associated with up-regulation of γ-glutamylcysteine ligase via constitutive NF-κB activation. J. Biol. Chem.279(37), 38779–38786 (2004).
   PubMed Web of Science ®Google Scholar
• Rojo AI, Salinas M, Marin D, Perona R, Guadrado A. Regulation of Cu/Zn-superoxide dismutase expression via the phosphatidylinositol 3 kinase/Akt pathway and nuclear factor-κB. J. Neurosci.24(33), 7324–7334 (2004).
   PubMed Web of Science ®Google Scholar
• Hoffmann A, Leung TH, Baltimore S. Genetic analysis of NF-κB/Rel transcription factors defines functional species. EMBO J.22(20), 5530–5539 (2003).
   PubMed Web of Science ®Google Scholar
• Sharma SK, Carlson EC, Ebadi M. Neuroprotective actions of selegiline in inhibiting 1-methyl,4-phenylpyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons. J. Neurocytol.32(4), 329–343 (2003).
   PubMedGoogle Scholar
• Chong ZZ, Meise K. Erythropietin requires NF-κB and its nuclear translocation to prevent early and late apoptotic neural injury during β-amyloid toxicity. Curr. Neurosci. Res.2(5), 387–399 (2005).
   PubMed Web of Science ®Google Scholar
• Henn IG, Bouman L, Schlehe J et al. Parkin mediates neuroprotection through activation of IκB kinase/nuclear factor-κB signaling. J. Neurosci.27(8), 1868–1878 (2007).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Weinstock M, Youdim MBH, Nagai M, Naoi M. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)- aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci. Lett.341(3), 233–236 (2003).
   PubMed Web of Science ®Google Scholar
• Chiou SH, Ku HH, Tsai TH et al. Moclobemide upregulated Bcl-2 expression and induce neural stem cell differentiation into serotoninergic neurons via extracellular-regulated kinase pathway. Br. J. Pharmacol.148(5), 587–598 (2006).
   PubMed Web of Science ®Google Scholar
• Mallajosyula JK, Kauer D, Chinta SJ et al., MAO-B elevation in mouse brain astrocytes results in Parkinson’s pathology. PLoS One3(2), E1616 (2008).
   PubMed Web of Science ®Google Scholar
• Fornsi F, Giogi FS, Gesi M, Chen K, Alessri MG, Shih JC. Biochemical effects of the monoamine neurotoxins DSP-4 and MDMA in specific brain regions of MAO-B-deficient mice. Synapse39(3), 213–221 (2001).
   PubMedGoogle Scholar
• Yi H, Akao Y, Maruyama W, Chen K, Shih, Naoi M. Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells. J. Neurochem.96(2), 541–549 (2006).
   PubMed Web of Science ®Google Scholar
• Maragos WF, Young KL, Altman CS et al. Striatal damage and oxidative stress induced by the mitochondrial toxin malonate are reduced in clorgyline-treated rats and MAO-A deficient mice. Neurochem. Res.29(4), 741–746 (2004).
   PubMed Web of Science ®Google Scholar
• Fitzgerald JC, Ufer C, De Girolamo LA, Kuhn H, Billet EE. Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells. J. Neurochem.103(6), 2189–2199 (2007).
   PubMed Web of Science ®Google Scholar
• Ou XM, Chen K, Shih JC. Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc. Natl Acad. Sci. USA103(29), 10923–10928 (2006).
   PubMed Web of Science ®Google Scholar
• Chen K, Ou XM, Chen G, Choi SH, Shih JC. R1, a novel repressor of the human monoamine oxidase A. J. Biol. Chem.280(12), 11552–11559 (2005).
   PubMedGoogle Scholar
• Wong WK, Ou XM, Chen K, Shih JC. Activation of human monoamine oxidase B gene expression by a protein kinase C MAPK signal transduction pathway involves c-Jun and Egr-1. J. Biol. Chem.277(25), 22222–22230 (2002).
   PubMed Web of Science ®Google Scholar
• Jiang H, Jiang Q, Liu W, Feng J. Parkin suppresses the expression of monoamine oxidases. J. Biol. Chem.281(13), 8591–8599 (2006).
   PubMed Web of Science ®Google Scholar
• Holt A, Berry MD, Boulton AA. On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited. Neurotoxicology25(1–2), 251–266 (2004).
   PubMed Web of Science ®Google Scholar
• Holt A, Wieland B, Baker GB. Allosteric modulation of semicarbazide-sensitive amine oxidase activities in vitro by imidazoline receptor ligands. Br. J. Pharmacol.143(4), 495–507 (2004).
   PubMed Web of Science ®Google Scholar
• Anderson NJ, Lupo PA, Nutt DJ, Hudson AL, Robinson ESL. Characterisation of imidazoline I2 binding sites in pig brain. Eur. J. Pharmacol.519(1–2), 68–74 (2004).
   Google Scholar
• Anderson NJ, Seif I, Nutt DJ, Hudson AL, Robinson ES. Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice. J. Neurochem.96(6), 1551–1559 (2006).
   PubMed Web of Science ®Google Scholar
• Hara MR, Thomas B, Cacio MB et al. Neuroprotection by pharmacologic blockade of the GADPH death cascade. Proc. Natl Acad. Sci. USA103(81), 3887–3889 (2006).
   PubMed Web of Science ®Google Scholar
• Hara M, Snyder SH. Nitric oxide-GAPDH-Siah: a novel cell death cascade. Cell Mol. Neurobiol.26(4–6), 527–538 (2006).
   PubMed Web of Science ®Google Scholar
• Levant B, Morgan KA, Ahlgren-Beckendorf JA et al Modulation of [3H]quinopirole binding at striatal D2 dopamine receptor by a monoamine-A-like site: evidence from radioligand studies and D2-receptor- and MAO(A)-deficient mice. Life Sci.70(2), 229–241 (2001).
   PubMedGoogle Scholar
• Ohta K, Kuno S, Mizuta I, Fujinami A, Matsui H, Ohta M. Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes. Life Sci.73(5), 517–626 (2003).
   Google Scholar
• Ohta K, Fujinami A, Kuno S et al. Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture. Pharmacology71(3), 162–168 (2004).
   PubMed Web of Science ®Google Scholar
• Jorda EG, Jimenez A, Verdaguer E et al. Evidence in favour of a role for peripheral-type benzodiazepine receptor ligands in amplification of neural apoptosis. Apoptosis10(1), 91–104 (2005).
   PubMed Web of Science ®Google Scholar
• Michell AW, Lewis SJG, Foltynie T, Barker RA. Biomarkers and Parkinson’s disease. Brain127(8), 1693–1705 (2004).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. The TEMPO study. A controlled trial of rasagiline in early Parkinson’s disease. Arch. Neurol.59(12), 1937–1943 (2002).
   PubMed Web of Science ®Google Scholar
• Stern MB, Marek KL, Friedman J et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson’s disease patients. Mov. Dis.19(8), 916–923 (2004).
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Melamed E et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily study): a randomized, double-blind, parallel-group trial. Lancet365(9463), 947–954 (2005).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch. Neurol.62(2), 241–249 (2005).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol.61(4), 561–566 (2004).
   PubMed Web of Science ®Google Scholar
• Clarke CE. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson’s disease. Lancet Neurol.3(8), 466–474 (2004).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA287(13), 1653–1661 (2002).
   PubMed Web of Science ®Google Scholar
• Whone A, Watts R, Stoessl J et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa; the REAL-PET study. Ann. Neurol.54(1), 93–101 (2003).
   PubMed Web of Science ®Google Scholar
• Jesse S, Steinacker P, Lehnert S, Gillardon F, Hengerer B, Otto M. Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review. CNS Neurosci. Ther.15(2), 157–182 (2009).
   PubMedGoogle Scholar
• Tokuda T, Alem SA, Alsop D et al. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. Biochem. Biophys. Res. Commun.349(1), 162–165 (2006).
   PubMed Web of Science ®Google Scholar
• Waragai M, Wei J, Fujita M et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson’s disease. Biochem. Biophys. Res. Commun.345(3), 967–972 (2006).
   PubMed Web of Science ®Google Scholar
• Waragai M, Nakai M, Wei J et al. Increased level of DJ-1 as a possible marker for progression of sporadic Parkinson’s disease. Neurosci. Lett.425(1), 18–22 (2007).
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W. Mitochondria and survival and death of dopamine neurons. Presented at: Dopamine 50 Years. Göteborg, Sweden 30 May–2 June 2007.
   Google Scholar
• Naoi M, Maruyama W, Riederer P. Cellular and animal models of Parkinson’s disease: a novel role of neuromelanin in degeneration of nigral dopamine neurons and finding of markers for neuroprotection. Presented at: The XXVI Collegium Internationale Neuro-psychopharmacologicum (CINP Congress). Munich, Germany 13–17 July 2008.
   Google Scholar
• Sanz E, Quintana A, Battaglia V et al. Anti-apoptotic effect of MAO-B inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxyl-indolyl), methylamine] is meditated by p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergic cells. J. Neurochem.105(6), 2405–2417 (2008).
   Google Scholar
• Chimenti F, Bolasco A, Manna F. et al. Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors. Curr. Med. Chem.13(12), 1411–1428 (2006).
   PubMed Web of Science ®Google Scholar
• Regina GL, Silverstri R, Artico M et al. New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinations of MAO-A and MAO-B selectivity. J. Med. Chem.50(5), 922–931 (2007).
   PubMedGoogle Scholar
• Binda C, Wang J, Pisani L, Caccia C et al. Structures of human oxidase B complexes with selective noncovalent inhibitors: sulfinamide and coumarin analogs. J. Med. Chem.50(23), 5848–5852 (2007).
   PubMed Web of Science ®Google Scholar
• Gallardo-Godoy A, Fierri A et al. Sulfur-substituted α-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling. J. Med. Chem.48(7), 2407–2419 (2005).
   PubMed Web of Science ®Google Scholar
• Regina GL, Silvestri R, Gatti V et al. Synthesis, structure–activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg. Med. Chem.16(22), 9729–9740 (2008).
   PubMedGoogle Scholar
• Binda C, Wang J, Li M, Hubalek F, Mattevi A, Edmonson DE. Structural and mechanistic studies of aryalkylhydrazine inhibition of human monoamine oxidases A and B. Biochemistry47(20), 5616–5625 (2008).
   PubMedGoogle Scholar
• Youdim MBH, Buccafusco JJ. CNS targets for multi-functional drugs in the treatment of Alzheimer’s and Parkinson’s diseases. J. Neural Transm.112(4), 519–537 (2005).
   PubMed Web of Science ®Google Scholar
• Van der Schyf C, Geldenhuys WJ, Youdim MBH. Mutlifunctional drugs with different CNS targets for neuropsychiatric disorders. J. Neurochem.99(4), 1033–1048 (2006).
   PubMed Web of Science ®Google Scholar
• Tsunekawa H, Noda Y, Mouri A, Yoneda F, Nabeshima T. Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid β (25–35). Behavior. Brain Res.190(2), 224–232 (2008).
   PubMedGoogle Scholar
• Sagi Y, Drigues N, Youdim MB. The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats. Br. J. Pharmacol.146(4), 553–560 (2005).
   PubMedGoogle Scholar
• Bar-Am O, Weinreb O, Amit T, Youdim MB. The novel cholinesterase-monoamine oxidase inhibitor and anti-oxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats. J. Mol. Neurosci.37(2), 135–145 (2009).
   PubMed Web of Science ®Google Scholar
• Mandel S, Amit T, Bar-Am O, Youdim MBH. Iron dysregulation in Alzheimer’s disease; multimodal brain permeable iron chelating drugs, possessing neuroprotective–neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog. Neurobiol.82(6), 348–360 (2007).
   PubMed Web of Science ®Google Scholar
• Shacar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology46(2), 254–263 (2004).
   PubMedGoogle Scholar
• Zheng H, Weiner LM, Bar-Am O et al. Design, synthesis, and evaluation of novel bifunctional iron-chelators, as potential agents for neuroprotecti in vivo on in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. Bioorg. Med. Chem.13(3), 773–783 (2005).
   PubMed Web of Science ®Google Scholar
• Gal S, Zheng H, Fridkin M, Youdim MBH. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem.95(1), 79–88 (2005).
   PubMed Web of Science ®Google Scholar
• Zhu W, Xie W, Pan T et al. Prevention and restoration of lactacystin-induced nigro–striatal dopamine neuron degeneration by novel-permeable iron chelators. FAESB J.21(14), 3835–3844 (2007).
   Google Scholar
• Yogev-Falach M, Amit T, Bar-Am O, Youdim MBH. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing. FASEB J.17(15), 23225–23227 (2003).
   Google Scholar
• Amit T, Avramovich-Tirosh Y, Youdim MB, Mandel S. Targeting multiple Alzheimer’s disease etiologies with multimodel neuroprotective and neurorestorative iron chelators. FASEB J.22(5), 1296–1305 (2007).
   PubMedGoogle Scholar
• Bar Am O, Amit T, Youdim MBH. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett.355(3), 169–172 (2004).
   PubMed Web of Science ®Google Scholar
• Mandel S, Amit T, Kalfon L, Youdim MBH. Applying transcritomic and proteomic knowledge to Parkinson’s disease drug discovery. Expert Opin. Drug Discov.2(9), 1–16 (2009).
   Google Scholar
• Kupsch A, Sautter J, Götz ME et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TV-1012) with selegiline. J. Neural Transm.108(8-9), 985–1009 (2001).
   PubMed Web of Science ®Google Scholar
• Eliash S, Sehteter N, Eilam R. Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model J. Neural Transm.112(8) 991–1003 (2005).
   PubMedGoogle Scholar
• Eliash J, Dror V, Cohen S, Behavi M. Neuroprotection by rasagiline in thiamine deficient rats. Brain Res.1256, 138–148 (2009).
   PubMed Web of Science ®Google Scholar
• Srefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotective in a transgenic model of multiple system sclerosis. Exp. Neurol.210(2) 421–427 (2007).
   PubMedGoogle Scholar
• Maruyama W, Akao Y, Youdim MB, Naoi M. Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J. Neural Transm. Suppl.60, 171–186 (2000)
   Google Scholar
• Maruyama W, Youdim MB, Naoi M. Antiapoptotic properties of rasagiline, N-propargyl-1(R )-aminoindan, and its optical (S)-enaniomer. Ann. NY Acad. Sci.939, 320–329 (2001)
   PubMed Web of Science ®Google Scholar
• Abu-Raya S, Tabakman R, Blaugrund E, Trembovier V, Lazarovici P. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur. J. Pharmacol.434(3) 109–116 (2002).
   PubMed Web of Science ®Google Scholar
• Bonneh-Barkay D, Ziv N, Finberg JP. Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells. Neuropharmacology48(3) 406–416 (2005).
   PubMedGoogle Scholar
• Kleiner Y, Bar-Am O, Amit T et al. TV1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity. J. Cardiovasc. Pharmacol.52(3) 268–277 (2008).
   PubMedGoogle Scholar
• Bar-Am O, Weinreb O, Amit T, Youdim MB. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neuroresue activity of propargylamines. FASEB J.19(13) 1899–1901 (2005).
   PubMed Web of Science ®Google Scholar
• Sagi Y, Weinstock M, Youdim MB. Attenuation of MPTP-induced dopaminergic neuotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J. Neurochem.86(2) 190–197 (2003).
   Google Scholar
• Weinreb O, Bar-Am O, Amit T, Driques N, Sagi Y, Youdim MB. The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity. Chem. Biol. Interact.175(1-3) 318-–326 (2008).
   PubMedGoogle Scholar
• Haberle D, Szökö E, Halasz AS, Magyar K. The effect of low doses of (-)-deprenyl and its metabolites on DSP-4 toxicity. J. Neural Transm.108(11) 1239–1247 (2001).
   PubMedGoogle Scholar
• Hobbenaghi R, Tiraihi T. Neuroprotective effect of deprenyl in sensory neurons of axotomized dorsal root ganglion. Clin. Nuropharmacol.26(5) 263–269 (2003).
   PubMed Web of Science ®Google Scholar
• Kiray M, Bagriyanik HA, Pekcetin C, Ergur BU, Uysal N. Protective effects of deprenyl in transient cerebral ischemia in rats. Clin. J. Physiol.51(5) 275–281 (2008).
   Google Scholar
• He KJ, Uetsuka K, Nakayama H, Neural progenitor cells are protected against MPTP by MAO-B inhibitors. Neurotoxicology29(6) 1141–1146 (2008).
   PubMedGoogle Scholar
• Saravanan KS, Sindhu KM, Senthikumar KS, Mohanakumar KP. L-deprenyl protects against rotenone-induced, oxidative-stress-mediated dopaminergic neurodegeneration in rats. Neurocehm. Int.49(1) 28–40 (2006).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Naoi M. Neuroprotection by (-)-deprenyl and related compounds. Mech. Ageing Dev.111(2-3) 189–200 (1999).
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W, Yagi K, Youdim M. Anti-apoptotic function of (-)-deprenyl (Selegiline) and related compounds. Neurobiology (Bp)8(1) 69–80 (2000).
   PubMedGoogle Scholar
• Chetsawang B, Kooncumchoo P, Govitrapong P, Ebadi M. 1-Methyl-4-phenyl-pyridinium ion-induced oxidative stress, c-Jun phosphorylation and DNA fragmentation factor-45 cleavage in SK-N-SH cells are averted by selegiline. Neurochem. Int.53(6–8) 283–288 (2008).
   PubMedGoogle Scholar
• Müller T, Przuntek H, Rieks M, Mackowiak A. Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells. Neurol. Res.30(4) 417–419 (2008).
   PubMed Web of Science ®Google Scholar
• Andringa G, Eshuis S, Perentes E et al. TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates. Neurobiol. Dis.14(2) 205–217 (2003).
   PubMedGoogle Scholar
• Sagot Y, Toni N, Perrelet D et al. An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease. Br. J. Pharmacol.131(4) 721–728 (2000).
   PubMed Web of Science ®Google Scholar
• Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol.132(2) 500–506 (2001).
   PubMed Web of Science ®Google Scholar
• Wu RM, Chiueh CC, Pert A, Murphy DL. Apparent antioxidant effect of l-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur. J. Pharmacol.243(3) 241–247 (1993).
   PubMed Web of Science ®Google Scholar
• Carrillo MC, Kanai S, Nokubo M, Kitani K, (-)Deprenyl induces activities of both superoxide dismutase and catalase but not glutathione peroxidase in the striatum of young male rats. Life Sci.48(6) 517–521 (1991).
   PubMed Web of Science ®Google Scholar
• Heikkila RE, Hess A, Duvoisin RC. Dopaminergic neurotoxicity of 1-methl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science224(4656) 1451–1453 (1984).
   PubMed Web of Science ®Google Scholar